Globus Medical, Inc. (GMED)

NYSE • Healthcare

$81.41

-$0.25 (-0.3%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$81.06

Day Range$80.4 - $82.01

Avg. Volume (3M)1.4M

Market Cap$10.9B

P/E Ratio20.5

52 Week Range

$59.51$101.4

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$789.6M100%

Gross Profitminus cost of goods$548.1M69%

Operating Incomeminus R&D and overhead$182.4M23%

Net Incomeminus taxes and the rest$151.5M19%

In plain terms: out of every $100 in revenue, Globus Medical, Inc. keeps $19 as net profit.

Fundamentals & Financials

Revenue (TTM)

$3.1B

Net Income (TTM)

$535.4M

EPS (TTM)

$3.97

ROA (TTM)

9.76%

Current Ratio

4.62

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+13.2%Q3 2025$0.86

+51.1%Q4 2025$1.18

+20.8%Q1 2026$1.28

+21.7%Q2 2026$1.12

+21.8%Q3 2026$1.34

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +21.8%

Globus Medical topped consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reporting on Aug. 6. Revenue rose about 6% to roughly $789.6 million, edging the about $782.9 million consensus by 0.9%, while gross margin held near 69% and operating margin was about 23%. Adjusted EPS of $1.34 topped the $1.10 estimate by about 22% and was up from $0.86 a year ago, even as net income fell roughly 25% to about $151.6 million from $202.8 million. Operating income reached about $182.4 million, operating cash flow came to about $412.1 million, and the company repurchased about $136.1 million of stock.

Next report — what to expect

Globus Medical, Inc. (GMED) reports earnings on November 5, 2026. Wall Street expects EPS of $1.20 on revenue of $792.2 million. For trailing context, revenue grew +5.9% year over year last quarter. GMED has beaten EPS in 7 of 8 most recent quarters, so focus on results versus those benchmarks.

View full earnings history

About Globus Medical, Inc.

Globus Medical, Inc. develops and sells musculoskeletal care devices and biologic products, trading on the NYSE under GMED in the healthcare sector. Its portfolio spans spine, trauma, joint reconstruction, and tissue-based offerings for patients worldwide, and it generated $2.9 billion of revenue in FY2025.

Name

Globus Medical, Inc.

CEO

Keith W. Pfeil

Website

www.globusmedical.com

Industry

Healthcare

Year Founded

2003

Employees

6,000

Today's Snapshot

AI-generated

GMED closed slightly lower at 81.39, while its sector was weaker. Trading was lighter than usual, with volume about half of its usual level.

Trading Volume

Below 10d avg (1.3M)

631.5K

vs S&P 500 Today

Moderate Outperformance

+0.19%

Updated: October 23, 2026 at 20:13 UTC

Technical Indicators

5 Buy1 Neutral2 Sell

GMED shows constructive short- to medium-term momentum that supports the buy signal despite some longer-term caution. Price sits above the short and intermediate moving averages while the MACD and CCI read positively, and the pivot level lies just below the market which is mildly constructive. However, the 200-day averages remain above the market and ADX around 22 signals a muted trend, while on-balance volume is negative and volatility is moderate (ATR ≈ 2.17). Technical takeaway: Buy — upward momentum and short-term moving-average support offset muted trend strength and weak volume.

All signals